Audited Financial Results for quarter and year March 31, 2026.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 20.1 pts more than Nifty Microcap 250 and 19.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Supriya Lifescience reported strong full-year performance with revenue from operations growing 18.9% to Rs 8,278.75 million from Rs 6,964.85 million. Net profit after tax increased 11.3% to Rs 2,091.20 million versus Rs 1,879.58 million in the prior year. EPS improved to Rs 25.98 from Rs 23.35. The company declared an unmodified audit opinion with no qualifications. The Board recommended a final dividend of Rs 1 per share (50% on face value Rs 2). An exceptional item of Rs 4.58 million was recognized due to the implementation of new labour codes effective November 2025, impacting employee benefit obligations.
The company delivered solid double-digit revenue and profit growth with a clean audit opinion, which is positive for shareholders. The dividend declaration provides income support. Strong operating cash flow of Rs 1,857.69 million indicates healthy cash generation.